Latest Breaking News On - Channel activator - Page 1 : comparemela.com

Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses.

United statesJason lernerJennifer porcelliMike beyerPrnewswire biohaven ltdExchange commissionDeterminants of healthAmerican epilepsy society annual meetingBiohaven therapeutics ltdAmerican epilepsy societySam brown incBiohaven ltdEpilepsy societyAnnual meetingMedical directorEpilepsy clinical lead